<DOC>
	<DOC>NCT00994214</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of repeated subcutaneous (under the skin) injections at different doses of BIM 23A760 on growth hormone and insulin-like growth factor-1 levels in patients with acromegaly after 6 months of treatment.</brief_summary>
	<brief_title>Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>IGF1 ≥1.3 x upper limit normal (ULN) Nadir serum GH concentration ≥0.4 ng/mL in an oral glucose tolerance test (OGTT) Patient must have documentation supporting the diagnosis of acromegaly, including elevated GH and/or insulinlike growth factor1 (IGF1) levels. The patient has received long acting somatostatin analogues within 6 months of study entry The patient has undergone radiotherapy at any time prior to study entry The time between pituitary surgery (if any) and study entry is less than 6 weeks The patient suffers from macroadenoma with visual field defects due to chiasmatic compression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>